

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,041,668 B2
APPLICATION NO. : 10/808889
DATED : May 9, 2006
INVENTOR(S) : Francois Clerc et al.

Page 1 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 1, Line 42 reads as:

“known substrate for cdk4 is the retinoblastonia gene product”

and should read as:

-- known substrate for CDK4 is the retinoblastoma gene product--


Column 1, Line 48 reads as:

“cycle progression, e.g. thymidine kinase, thymdylate syn-”


and should read as:

--cycle progression, e.g. thymidine kinase, thymidylate syn- --

Column 2, the structure beginning at Line 32 reads as:



and should read as:



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,041,668 B2
APPLICATION NO. : 10/808889
DATED : May 9, 2006
INVENTOR(S) : Francois Clerc et al.

Page 2 of 2

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3, Line 28 reads as:

“lamino sutstituent. In the preferred compounds of formula”

and should read as:

-- lamino substituent. In the preferred compounds of formula--

Column 160, Line 37 reads as:

“b 1-imidazolyl” and should read as:

--1-imidazolyl--

Column 164, Line 33 reads as:


“cyclopentylamino and R₂ is aryl a aralkyl optionally substi-”

and should read as:

--cyclopentylamino and R₂ is aryl or aralkyl optionally substi- --

Signed and Sealed this

Seventeenth Day of October, 2006



JON W. DUDAS
Director of the United States Patent and Trademark Office